How Investors May Respond To Apellis Pharmaceuticals (APLS) Balancing EMPAVELI’s FDA Win With Slow Rare-Disease Uptake

Simply Wall St.01-22

Apellis Pharmaceuticals recently secured US FDA approval for EMPAVELI to treat the rare kidney diseases C3 glomerulopathy and IC-MPGN, the first and only approved therapy for these conditions, while ...

Source Link
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment